Experimental evaluation of coronary thrombodynamics and effects of pharmacological interventions in acute coronary syndromes.
Intracoronary thrombodynamics in acute coronary syndromes was studied with an experimental canine model. An intracoronary thrombus was precipitated at the mock ruptured atheromatous plaque consisting of cholesterol and collagen. In 8 of 10 control models, acute myocardial infarction (AMI) was induced by intracoronary occlusive thrombus 1 h after the start of the experiment. Coronary blood flow decreased continuously (Type A, n = 5) or cyclically (Type B, n = 3) to end in AMI. Effects of pharmacological interventions to prevent AMI were also studied with the model. An intravenous bolus injection of a thromboxane synthetase inhibitor (RS-5186), heparin, a thrombin inhibitor (argatroban), and a thrombolytic agent (urokinase) was performed in 10 models for each drug. The incidence of AMI was significantly decreased to 3 of the 10 models injected with the thromboxane synthetase inhibitor and heparin (p < .05, each drug group vs. control). The preventive effect of argatroban was more potent and AMI occurred in 2 of 10 models (p < 0.01, argatroban vs control).
Tomoda
H
H
Department of Cardiology, Tokai University, Kanagawa, Japan.
D000818:Animals; D000991:Antithrombins / Q000008:administration & dosage / Q000494:pharmacology; D001120:Arginine / Q000031:analogs & derivatives; D003326:Coronary Circulation / Q000187:drug effects; D003328:Coronary Thrombosis / Q000150:complications; D004285:Dogs; D006493:Heparin / Q000008:administration & dosage* / Q000494:pharmacology; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D010875:Pipecolic Acids / Q000008:administration & dosage / Q000494:pharmacology; D013449:Sulfonamides; D013876:Thiophenes / Q000008:administration & dosage* / Q000494:pharmacology; D015912:Thrombolytic Therapy; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000494:pharmacology
D000991:Antithrombins; D010875:Pipecolic Acids; D013449:Sulfonamides; D013876:Thiophenes; C055806:RS 5186; D006493:Heparin; D001120:Arginine; D014568:Urokinase-Type Plasminogen Activator; D013930:Thromboxane-A Synthase; C031942:argatroban